Scorpius Holdings (Scorpius Holdings) GF Score : 37/100 (As of Jun. 10, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings GF Score?

Scorpius Holdings has the GF Score of 37, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 3/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Scorpius Holdings might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Scorpius Holdings's GF Score

For the Biotechnology subindustry, Scorpius Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scorpius Holdings's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's GF Score falls into.

Scorpius Holdings (AMEX:SCPX) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Scorpius Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Scorpius Holdings (Scorpius Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

1HB:Germany

Address

627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560

Website

https://www.nighthawkbio.com

NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.

Executives

Prendergast John K A	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf	director, officer: Chief Executive Officer	3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii	director	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander	officer: CFO/Corp Secy	801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan	director
Robert James Jakobs	officer: VP Finance/Controller/Secty	PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins	officer: Chief Scientific Officer	15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar	officer: VP of Finance and Controller	C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov	director	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech	officer: Chief Financial Officer	C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber	officer: Vice President of Research	100 EUROPA DRIVE, CHAPEL HILL NC 27517